Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Seres Therapeutics Inc (MCRB)

Seres Therapeutics Inc (MCRB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 653,039
  • Shares Outstanding, K 91,719
  • Annual Sales, $ 33,220 K
  • Annual Income, $ -89,130 K
  • 60-Month Beta 3.98
  • Price/Sales 17.98
  • Price/Cash Flow N/A
  • Price/Book 6.06
Trade MCRB with:

Options Overview

Details
  • Implied Volatility 92.53%
  • Historical Volatility 87.28%
  • IV Percentile 15%
  • IV Rank 17.73%
  • IV High 206.17% on 07/16/21
  • IV Low 68.03% on 09/03/21
  • Put/Call Vol Ratio 0.16
  • Today's Volume 307
  • Volume Avg (30-Day) 377
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 7,923
  • Open Int (30-Day) 11,295

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.47
  • Number of Estimates 5
  • High Estimate -0.40
  • Low Estimate -0.54
  • Prior Year -0.36
  • Growth Rate Est. (year over year) -30.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.41 +24.03%
on 09/14/21
7.15 -6.15%
on 09/17/21
+0.63 (+10.36%)
since 08/20/21
3-Month
5.41 +24.03%
on 09/14/21
25.06 -73.22%
on 06/30/21
-15.12 (-69.26%)
since 06/18/21
52-Week
5.41 +24.03%
on 09/14/21
38.50 -82.57%
on 11/18/20
-18.94 (-73.84%)
since 09/18/20

Most Recent Stories

More News
Seres Therapeutics Achieves Enrollment of 300 Subjects with Phase 3 ECOSPOR IV Open-Label Extension Study of SER-109, a Potentially First-in-Class Investigational Microbiome Therapeutic for Recurrent C. difficile Infection

--- Potential to be first-ever FDA-approved microbiome therapy -

MCRB : 6.71 (-5.76%)
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will participate in three upcoming investor conferences:

MCRB : 6.71 (-5.76%)
Seres Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Eric Shaff, President and Chief Executive Officer of Seres Therapeutics, will participate in a discussion...

MCRB : 6.71 (-5.76%)
Seres Therapeutics (MCRB) Reports Q2 Loss, Tops Revenue Estimates

Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -29.27% and 19.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

MCRB : 6.71 (-5.76%)
Seres Therapeutics: Q2 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Seres Therapeutics Inc. (MCRB) on Tuesday reported a loss of $48.3 million in its second quarter.

MCRB : 6.71 (-5.76%)
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates

--- SER-109 co-commercialization agreement with Nestle Health Science provides $310 million in upfront and contingent approval milestones, additional $225 million in contingent sales milestones, and future...

MCRB : 6.71 (-5.76%)
Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021

Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on August 3, 2021 at 8:30 a.m. ET...

MCRB : 6.71 (-5.76%)
Biotech Stock Roundup: BIIB's Q2 Earnings Update & Other Updates From AMGN, INCY

The biotech sector was in focus last week on earnings results from Biogen (BIIB) and updates from Incyte (INCY) and others.

BIIB : 297.00 (-1.06%)
AMGN : 216.95 (-1.11%)
INCY : 75.99 (+1.27%)
MRNA : 413.75 (-3.79%)
MCRB : 6.71 (-5.76%)
IONS : 37.21 (+2.14%)
Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast today at 8:30 a.m. ET to discuss topline...

MCRB : 6.71 (-5.76%)
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis

----Both dosing regimens of SER-287 were generally well tolerated--

MCRB : 6.71 (-5.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 8.22
2nd Resistance Point 7.69
1st Resistance Point 7.40
Last Price 6.71
1st Support Level 6.58
2nd Support Level 6.05
3rd Support Level 5.76

See More

52-Week High 38.50
Fibonacci 61.8% 25.86
Fibonacci 50% 21.95
Fibonacci 38.2% 18.05
Last Price 6.71
52-Week Low 5.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar